NCT05148598View on ClinicalTrials.gov

ADRCs in The Treatment of Hand Dysfunction Due to Scleroderma

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

174

Participants

Timeline

Start Date

February 28, 2023

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2025

Conditions
Scleroderma, Diffuse
Interventions
DEVICE

ADRCs

Adipose Derived Regenerative Cells (ADRCs) processed with Celution System

OTHER

Standard Care

Standard care

OTHER

Placebo

Placebo visually indistinguishable from ADRCs

Sponsors

Lead Sponsor

Paracrine, INC.
All Listed Sponsors
lead

Paracrine, INC.

INDUSTRY

NCT05148598 - ADRCs in The Treatment of Hand Dysfunction Due to Scleroderma | Biotech Hunter | Biotech Hunter